IMRNW - (Immuron Limited)

 IMRNWのチャート


 IMRNWの企業情報

symbol IMRNW
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear 2017年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/imrnw
adr_tso
EBITDA EBITDA ー
終値(lastsale) 2.5
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 IMRNWのテクニカル分析


 IMRNWのニュース

   Immuron shares rise after highlighting study describing antiviral benefits of IMM-124E  2021/10/08 13:57:21 Seeking Alpha
   Immuron''s IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19  2021/10/08 12:10:03 Benzinga
Immuron Limited (NASDAQ: IMRN ) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical Center, Israel. IMM124E is used to manufacture Immuron''s flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn. The paper examines the ability of Full story available on Benzinga.com
   Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data  2021/10/08 02:52:01 The Motley Fool Australia
New research suggests the company''s drug might be able to treat COVID-19 The post Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data appeared first on The Motley Fool Australia .
   Immuron Director resignation  2021/09/24 03:00:00 Intrado Digital Media
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou.
   Immuron down 15% after abandoning planned acquisition due to listing requirements  2021/09/23 15:36:49 Seeking Alpha
   Immuron shares rise after highlighting study describing antiviral benefits of IMM-124E  2021/10/08 13:57:21 Seeking Alpha
   Immuron''s IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19  2021/10/08 12:10:03 Benzinga
Immuron Limited (NASDAQ: IMRN ) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical Center, Israel. IMM124E is used to manufacture Immuron''s flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn. The paper examines the ability of Full story available on Benzinga.com
   Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data  2021/10/08 02:52:01 The Motley Fool Australia
New research suggests the company''s drug might be able to treat COVID-19 The post Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data appeared first on The Motley Fool Australia .
   Immuron Director resignation  2021/09/24 03:00:00 Intrado Digital Media
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou.
   Immuron down 15% after abandoning planned acquisition due to listing requirements  2021/09/23 15:36:49 Seeking Alpha

 関連キーワード  (― 米国株 IMRNW Immuron Limited)

 twitter  (公式ツイッターやCEOツイッターなど)